TriangleNCT03228537 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Duration of treatment and follow-up until death or 3 years post Step 1 registration.
What was measured
From date of registration to Step 1 to date of first documentation of progression by RECIST 1.1 and modified RECIST 1.1, symptomatic deterioration, or death due to any cause. Participants last known to be alive and progression free are censored at date of last disease assessment.
Analysis population: Eligible and evaluable participants.
Groups in this outcome
Treatment (Chemotherapy, Surgery +/- RT, Maintenance)
NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity. SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy. MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.
| Group | Source count |
|---|---|
| Treatment (Chemotherapy, Surgery +/- RT, Maintenance) | 28 |
Reported measurements
RECIST 1.1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Chemotherapy, Surgery +/- RT, Maintenance) | 9.5 | Not reported | 6.6 | 13.0 | Not reported |
mRECIST 1.1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Chemotherapy, Surgery +/- RT, Maintenance) | 18.4 | Not reported | 6.6 | 25.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.6
- upper Limit
- 13.0
- value
- 9.5
- title
- RECIST 1.1
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.6
- upper Limit
- 25.1
- value
- 18.4
- title
- mRECIST 1.1
- denoms
- counts
- group Id
- OG000
- value
- 28
- units
- Participants
- description
- From date of registration to Step 1 to date of first documentation of progression by RECIST 1.1 and modified RECIST 1.1, symptomatic deterioration, or death due to any cause. Participants last known to be alive and progression free are censored at date of last disease assessment.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity. SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy. MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.
- id
- OG000
- title
- Treatment (Chemotherapy, Surgery +/- RT, Maintenance)
- param Type
- MEDIAN
- population Description
- Eligible and evaluable participants.
- reporting Status
- POSTED
- time Frame
- Duration of treatment and follow-up until death or 3 years post Step 1 registration.
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice